Pages that link to "Q42260010"

The following pages link to Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism (Q42260010):

Displaying 24 items.

• Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand (Q24598661) (← links)
• What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs (Q33278984) (← links)
• Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesis (Q33589580) (← links)
• Bromocriptine: old drug, new formulation and new indication (Q34145883) (← links)
• Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes (Q34718312) (← links)
• Ergot alkaloids produced by endophytic fungi of the genus Epichloë. (Q35232716) (← links)
• Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans (Q36533717) (← links)
• Anti-Parkinson's disease drugs and pharmacogenetic considerations (Q38097097) (← links)
• Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease (Q38748158) (← links)
• Pharmacokinetic optimisation in the treatment of Parkinson's disease (Q40937861) (← links)
• Toxicity of endophyte-infected ryegrass hay containing high ergovaline level in lactating ewes. (Q40964734) (← links)
• High-Level Production and Properties of the Cysteine-Depleted Cytochrome P450 3A4. (Q46445841) (← links)
• The advantages of the Ussing chamber in drug absorption studies (Q46644570) (← links)
• Growth and hepatic in vitro metabolism of ergotamine in mice divergently selected for response to endophyte toxicity (Q46726514) (← links)
• Scientific Opinion on Ergot alkaloids in food and feed (Q47152050) (← links)
• A therapeutic combination of GPCR modulators that protects photoreceptors from degeneration (Q47377556) (← links)
• Quercetin nanoparticles alter pharmacokinetics of bromocriptine, reflecting its enhanced inhibitory action on liver and intestinal CYP 3A enzymes in rats (Q47851974) (← links)
• Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum (Q49161595) (← links)
• Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes (Q51551827) (← links)
• High-performance liquid chromatographic assay of bromocriptine in rat plasma and brain (Q70255726) (← links)
• Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man (Q70484556) (← links)
• Interspecies similarities in the disposition of 3H-dihydroergotamine following subcutaneous administration in man and rabbits (Q71324254) (← links)
• High-performance liquid chromatographic assay of bromocriptine in plasma and eye tissue of the rabbit (Q73574773) (← links)
• Meta-Analysis of Pharmacokinetic Studies of Nanobiomaterials for the Prediction of Excretion Depending on Particle Characteristics (Q92542718) (← links)